Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Completed

Conditions studied: Osteoporosis, Bone Fracture

In brief

The purpose of this study is to validate the long-term benefit of denosumab for osteoporosis treatment in a real-world clinical practice setting. We hypothesize that continued therapy (36+months) with denosumab will increase both trabecular bone score (TBS) and femur strength index (FSI) and reduce fracture and other bone health risks among post-menopausal women with osteoporosis.

Key facts

Study ID
NCT02435147
Run by
HealthEast Care System
People needed
86
Starts
2015-04-01
Expected to finish
2016-06-01
Last updated by the study team
2018-10-29

Who can join

Age: 40 and older, up to 90. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.